Literature DB >> 10906014

Twelve year outcomes following bacterial meningitis: further evidence for persisting effects.

K Grimwood1, P Anderson, V Anderson, L Tan, T Nolan.   

Abstract

AIM: To determine whether intellectual and cognitive impairments observed seven years following early childhood bacterial meningitis persist into adolescence.
METHODS: Blinded neuropsychological, auditory, and behaviour assessments were conducted in 109 (69%) subjects from an original cohort of 158 children, seven and 12 years after their meningitis, and in 96 controls.
RESULTS: Meningitis subjects remained at greater risk than controls for any disability (odds ratio OR 4.7, confidence interval 2.2 to 9.6). Those with acute neurological complications had more sequelae than children with uncomplicated meningitis or controls (47% v 30% v 11.5% respectively; p < 0.001). Differences in intellectual, academic, and high level cognitive function between subjects and controls were maintained at the seven and 12 year assessments. In contrast, lower order skills improved, while behaviour scores deteriorated significantly (p = 0.033).
CONCLUSIONS: Many of the deficits identified at the seven year follow up persist 12 years after an episode of bacterial meningitis.

Entities:  

Mesh:

Year:  2000        PMID: 10906014      PMCID: PMC1718445          DOI: 10.1136/adc.83.2.111

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  18 in total

1.  The sequelae of Haemophilus influenzae meningitis in school-age children.

Authors:  H G Taylor; E L Mills; A Ciampi; R du Berger; G V Watters; R Gold; N MacDonald; R H Michaels
Journal:  N Engl J Med       Date:  1990-12-13       Impact factor: 91.245

Review 2.  Long-term effects of meningitis.

Authors:  P A Davies
Journal:  Dev Med Child Neurol       Date:  1989-06       Impact factor: 5.449

3.  Four-year follow-up of an epidemiological sample.

Authors:  F C Verhulst; H M Koot; G F Berden
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1990-05       Impact factor: 8.829

4.  Summary statement: The First International Conference on Haemophilus influenzae type b infection in Asia.

Authors:  D M Salisbury
Journal:  Pediatr Infect Dis J       Date:  1998-09       Impact factor: 2.129

5.  Academic achievement in children ten to 12 years after Haemophilus influenzae meningitis.

Authors:  H M Feldman; R H Michaels
Journal:  Pediatrics       Date:  1988-03       Impact factor: 7.124

6.  Progressive hearing loss following Haemophilus influenzae meningitis.

Authors:  E D Silkes; J Chabot
Journal:  Int J Pediatr Otorhinolaryngol       Date:  1985-08       Impact factor: 1.675

7.  Outcomes of bacterial meningitis in children: a meta-analysis.

Authors:  L J Baraff; S I Lee; D L Schriger
Journal:  Pediatr Infect Dis J       Date:  1993-05       Impact factor: 2.129

8.  Audiovestibular and neuropsychological outcome of adults who had recovered from childhood bacterial meningitis.

Authors:  S Hugosson; E Carlsson; E Borg; L O Brorson; G Langeroth; P Olcén
Journal:  Int J Pediatr Otorhinolaryngol       Date:  1997-12-10       Impact factor: 1.675

9.  Long-term outcome of Haemophilus influenzae meningitis in Navajo Indian children.

Authors:  C T D'Angio; R G Froehlke; G A Plank; D J Meehan; C M Aguilar; M B Lande; L Hugar
Journal:  Arch Pediatr Adolesc Med       Date:  1995-09

10.  Adverse outcomes of bacterial meningitis in school-age survivors.

Authors:  K Grimwood; V A Anderson; L Bond; C Catroppa; R L Hore; E H Keir; T Nolan; D M Roberton
Journal:  Pediatrics       Date:  1995-05       Impact factor: 7.124

View more
  57 in total

Review 1.  Non-traumatic coma in children.

Authors:  F J Kirkham
Journal:  Arch Dis Child       Date:  2001-10       Impact factor: 3.791

2.  Legacy of bacterial meningitis in infancy. Many children continue to suffer functionally important deficits.

Authors:  K Grimwood
Journal:  BMJ       Date:  2001-09-08

Review 3.  Reprogramming the host response in bacterial meningitis: how best to improve outcome?

Authors:  M van der Flier; S P M Geelen; J L L Kimpen; I M Hoepelman; E I Tuomanen
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

4.  Use of corticosteroids and other adjunct therapies for acute bacterial meningitis in adults.

Authors:  Kameshwar Prasad; Nirendra Kumar Rai; Amit Kumar
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

5.  Adjunctive daptomycin attenuates brain damage and hearing loss more efficiently than rifampin in infant rat pneumococcal meningitis.

Authors:  Denis Grandgirard; Melchior Burri; Philipp Agyeman; Stephen L Leib
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

6.  Pathophysiology and treatment of bacterial meningitis.

Authors:  Olaf Hoffman; R Joerg Weber
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

7.  Effect of meningitis in infancy on school-leaving examination results.

Authors:  John de Louvois; Sue Halket; David Harvey
Journal:  Arch Dis Child       Date:  2007-03-22       Impact factor: 3.791

8.  Restoration of Akt activity by the bisperoxovanadium compound bpV(pic) attenuates hippocampal apoptosis in experimental neonatal pneumococcal meningitis.

Authors:  Matthias D Sury; Lorianne Vorlet-Fawer; Claudia Agarinis; Shida Yousefi; Denis Grandgirard; Stephen L Leib; Stephan Christen
Journal:  Neurobiol Dis       Date:  2010-09-25       Impact factor: 5.996

Review 9.  Chemotactic factors in cerebrospinal fluid during bacterial meningitis.

Authors:  Petra J G Zwijnenburg; Tom van der Poll; John J Roord; A Marceline van Furth
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

10.  Edaravone attenuates hippocampal damage in an infant mouse model of pneumococcal meningitis by reducing HMGB1 and iNOS expression via the Nrf2/HO-1 pathway.

Authors:  Zheng Li; Qian-Qian Ma; Yan Yan; Feng-Dan Xu; Xiao-Ying Zhang; Wei-Qin Zhou; Zhi-Chun Feng
Journal:  Acta Pharmacol Sin       Date:  2016-08-29       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.